Table 3 Clinical and vaccination data from IPD patients, <5 years of age in NSW, from whom IPD serogroup 19 isolates were isolated.
Demographic & core clinical data | 2004 | 2008 | 2014 | |
---|---|---|---|---|
Total cases | n = 41 | n = 60 | n = 23 | |
Median age, years (range) | 1.45 (0.04–4.94)a | 1.76 (0.0–4.73) | 1.9 (0.0–5) | |
Specimen type | Bloodb | 40 (98%) | 59 (98%) | 21 (91.3%) |
Joint fluid | 1(2%) | 1 (2%) | — | |
CSF | — | — | 2 (8.7%) | |
Clinical presentation | Bacteremia | 22 (54%) | 31 (51.5%) | 11 (47.8) |
Pneumonia | 11 (27%) | 25 (41.5%) | 9 (39.1) | |
Septic arthritis | 1 (2%) | 1 (2%) | — | |
Meningitis | — | — | 2 (8.7) | |
Unknown | 7 (17%) | 3 (5%) | 1 (4.3) | |
Vaccination History | Full | 1 (2%) | 50 (82%) | 15 (65%) |
Partial | 2 (5%) | 6 (10%) | 5 (22%) | |
None | 31 (76%) | 1 (2%) | 2 (9%) | |
Unknown | 7 (17%) | 2 (3%) | 1 (4%) | |
PCV-7 history | 3 doses | 1 (2.4%) | 50 (83%) | 5 (23%) |
2 doses | — | 6 (10%) | 1 (4%) | |
1 dose | 1 (2.4%) | 1 (2%) | — | |
No PCV-7 | 29 (70.8%) | 2 (3%) | 16 (70%) | |
Unknown | 9 (22%) | 1 (2%) | 1 (4%) | |
PCV-13 history | 3 doses | — | — | 10 (44%) |
2 doses | — | — | 4 (17%) | |
1 dose | — | — | 1 (4%) | |
No PCV13 | — | — | 7 (30%) | |
Unknown | 1 (4%) | |||
PPV-23 history | 1 dose | 1 (2.4%) | — | — |
Immune status | Compromised | 3 (7%) | 1 (2%) | 2 (9%) |
Competent | 32 (78%) | 59 (98%) | 20 (87%) | |
Unknown | 6 (15%) | — | 1 (4%) | |
Indigenous statusc | Non-indigenous | 98% | 95% | 21 (91%) |
Indigenous | 2% | 5% | 2 (9%) |